Literature DB >> 19557830

Plasma facilitated delivery of DNA to skin.

Richard J Connolly1, Gabriel A Lopez, Andrew M Hoff, Mark J Jaroszeski.   

Abstract

Non-viral delivery of cell-impermeant drugs and DNA in vivo has traditionally relied upon either chemical or physical stress applied directly to target tissues. Physical methods typically use contact between an applicator, or electrode, and the target tissue and may involve patient discomfort. To overcome contact-dependent limitations of such delivery methodologies, an atmospheric helium plasma source was developed to deposit plasma products onto localized treatment sites. Experiments performed in murine skin showed that samples injected with plasmid DNA encoding luciferase and treated with plasma demonstrated increased levels of expression relative to skin samples that received injections of DNA alone. Increased response relative to injection alone was observed when either positive or negative voltage was used to generate the helium plasma. Quantitative results over a 26-day follow-up period showed that luciferase levels as high as 19-fold greater than the levels obtained by DNA injection alone could be achieved. These findings indicate that plasmas may compete with other physical delivery methodologies when skin is the target tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557830     DOI: 10.1002/bit.22451

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  11 in total

1.  Non-contact helium-based plasma for delivery of DNA vaccines. Enhancement of humoral and cellular immune responses.

Authors:  Richard J Connolly; Taryn Chapman; Andrew M Hoff; Michele A Kutzler; Mark J Jaroszeski; Kenneth E Ugen
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

2.  Direct Current Helium Plasma for In vivo Delivery of Plasmid DNA Encoding Erythropoietin to Murine Skin.

Authors:  Mark J Jaroszeski; Taryn Harvey-Chapman; Andrew Hoff; Reginald Atkins; Richard J Connolly
Journal:  Plasma Med       Date:  2017

3.  Optimization of a plasma facilitated DNA delivery method.

Authors:  Richard J Connolly; Andrew M Hoff; Richard Gilbert; Mark J Jaroszeski
Journal:  Bioelectrochemistry       Date:  2014-10-13       Impact factor: 5.373

4.  Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma.

Authors:  Richard J Connolly; Jose I Rey; Vance M Lambert; Garrett Wegerif; Mark J Jaroszeski; Kenneth E Ugen
Journal:  Vaccine       Date:  2010-12-31       Impact factor: 3.641

Review 5.  Membrane Oxidation in Cell Delivery and Cell Killing Applications.

Authors:  Ting-Yi Wang; M Daben J Libardo; Alfredo M Angeles-Boza; Jean-Philippe Pellois
Journal:  ACS Chem Biol       Date:  2017-04-10       Impact factor: 5.100

6.  Electrogenetherapy of B16.F10 murine melanoma tumors with an interleukin-28 expressing DNA plasmid.

Authors:  Kevin Shah; Richard J Connolly; Taryn Chapman; Mark J Jaroszeski; Kenneth E Ugen
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

7.  Plasma Permeabilization of Human Excised Full-Thickness Skin by µs- and ns-pulsed DBD.

Authors:  Monika Gelker; Christel C Müller-Goymann; Wolfgang Viöl
Journal:  Skin Pharmacol Physiol       Date:  2020-01-21       Impact factor: 3.479

8.  Delivery and expression of plasmid DNA into cells by a novel non-thermal plasma source.

Authors:  Eva Dolezalova; Muhammad A Malik; Loree Heller; Richard Heller
Journal:  Bioelectrochemistry       Date:  2021-04-05       Impact factor: 5.760

9.  Area-specific cell stimulation via surface-mediated gene transfer using apatite-based composite layers.

Authors:  Yushin Yazaki; Ayako Oyane; Yu Sogo; Atsuo Ito; Atsushi Yamazaki; Hideo Tsurushima
Journal:  Int J Mol Sci       Date:  2015-04-14       Impact factor: 5.923

10.  Plasma-activated air mediates plasmid DNA delivery in vivo.

Authors:  Chelsea M Edelblute; Loree C Heller; Muhammad A Malik; Anna Bulysheva; Richard Heller
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-13       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.